Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation

Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Transcranienne Par Courant Direct (tDCS) du Cortex Cerebelleux

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02052271

Acronym

ELECTRE2

Enrollment

Registered

2014-02-03

Start date

2014-06-03

Completion date

2018-03-27

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor

Keywords

essential tremor, cerebellum, transcranial direct current stimulation, electrophysiology

Brief summary

The purpose of this study is to determine whether transcranial cathodal direct current stimulation (tDCS) delivered over the cerebellum can improve essential tremor.

Interventions

DEVICECathodal cerebellar transcranial direct current placebo stimulation

Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;

DEVICECathodal cerebellar transcranial direct current active stimulation

Active stimulation: duration: 20 mn, intensity: 2 mA; localisation cerebellum;

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years and ≤ 65 years * Important essential tremor (bilateral postural and/or action tremor since more than one year) * Normal physical and neurological examination, except for essential tremor * Insufficient efficiency of usual essential tremor's treatment * No treatment altering the cortical excitability * Agreement to use a medically acceptable method of contraception throughout the study for female of childbearing potential * mini-mental status score \>24

Exclusion criteria

* Age \< 18 years and \> 65 years * Current neurological or psychiatric illness other than essential tremor * Individual who is on medication which is known to lower seizure threshold * Previous history of seizure, loss of conciousness or current active epilepsy * Contraindication for MRI or TMS study * Intake of antiepileptic medications for essential tremor (barbiturates, gabapentine, topiramate, clonazepam), within the 7 days preceeding the first visit * alcohol intake within the 24 hours preceeding the first visit * Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control * Individual who have MMS ≤ 24/30 or patients legally protected or inability to provide an informed consent * Simultaneous participation in another clinical trial * Patients who are not enrolled at social security

Design outcomes

Primary

Measure	Time frame
Change from baseline in tremor amplitude on clinical rating scale	10 minutes after the end of tDCS

Secondary

Measure	Time frame
Change from baseline in tremor amplitude on accelerometric recording	During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on electromyographic recordings	During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on digitized tablet	During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on clinical rating scale	During tDCS, 60 mn and 90 mn after the end of tDCS
Change from baseline of amplitude of motor evoked potentials elicited by TMS	10 mn, 60 mn and 90 mn after tDCS

Countries

France

Contacts

PRINCIPAL_INVESTIGATOREmmanuel Flamand-Roze, MD

Institut du Cerveau et de la Moelle et Fédération de Neurologie de l'Hôpital Pitié-Salpétrière, Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026